US › Healthcare

Heron Therapeuti (HRTX)

US · Healthcare · Biotechnology

$0.32-0.66%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$37.7M

Revenue YoY

+1.3%

Net profit

$-5.5M

EPS

$-0.03

EPS estimate

$-0.02

Net margin

-14.6%

EPS came in at -0.03 against a street estimate of -0.02 — a miss of 50.0%.

Key statistics

Market cap

$59.9M

Forward P/E

46.9

P/B

10.23

Book value

$0.03

EPS (TTM)

$-0.19

52-week high

$1.57

52-week low

$0.30

50-day MA

$0.40

200-day MA

$0.87

Beta

1.61

Analyst view

Analysts rate Heron Therapeuti a strong buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $7.00.

Shareholding

Insiders

0.98%

Institutions

71.03%

Largest institutional holders

Fund	Stake
Rubric Capital Management LP	15.83%
Clearline Capital LP	6.44%
BlackRock Inc	5.32%
Orbimed Advisors LLC	5.17%
Velan Capital Investment Management LP	4.61%
Vanguard Capital Management, LLC	4.11%
Tejara Capital Ltd	3.43%
TANG CAPITAL MANAGEMENT LLC	3.29%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Heron Therapeuti — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.